VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 1014-1023

  Currier, Mark A ^a,b   Eshun, Francis K ^a,c   Sholl, Allyson ^a   Chernoguz, Artur ^a   Crawford, Kelly ^a   Divanovic, Senad ^a   Boon, Louis ^d   Goins, William F ^e   Frischer, Jason S ^a   Collins, Margaret H ^a   Leddon, Jennifer L ^a,b   Baird, William H ^a   Haseley, Amy ^b   Streby, Keri A ^b   Wang, Pin Yi ^a,b   Hendrickson, Brett W ^b   Brekken, Rolf A ^f   Kaur, Balveen ^b   Hildeman, David ^a   Cripe, Timothy P ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c PHOENIX CHILDREN'S HOSPITAL   (United States)

^d BIOCEROS   (Netherlands)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD11B ANTIGEN; ONCOLYTIC HERPES VIRUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; BONE MARROW CELL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; RECEPTOR BLOCKING; SARCOMA; SARCOMA CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; VIROGENESIS;

SIMPLEXVIRUS;

EID: 84877024720     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.39     Document Type: Conference Paper

References (34)

1. Shen, Y and Nemunaitis, J (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13: 975-992.
2. Hammill, AM, Conner, J and Cripe, TP (2010). Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 55: 1253-1263.
3. Wuest, TR and Carr, DJ (2010). VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med 207: 101-115.
4. Cook, WJ, Kramer, MF, Walker, RM, Burwell, TJ, Holman, HA, Coen, DM et al. (2004). Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection. Virol J 1: 5.
5. Fenton, RR, Molesworth-Kenyon, S, Oakes, JE and Lausch, RN (2002). Linkage of IL-6 with neutrophil chemoattractant expression in virus-induced ocular inflammation. Invest Ophthalmol Vis Sci 43: 737-743.
6. Kim, B, Sarangi, PP, Lee, Y, Deshpande Kaistha, S, Lee, S and Rouse, BT (2006). Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation. J Leukoc Biol 80: 1405-1415.
7. Zheng, M, Deshpande, S, Lee, S, Ferrara, N and Rouse, BT (2001). Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75: 9828-9835.
8. Lee, S, Zheng, M, Kim, B and Rouse, BT (2002). Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 110: 1105-1111.
9. Solinas, G, Germano, G, Mantovani, A and Allavena, P (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073.
10. Mantovani, A and Sica, A (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237.
11. Doedens, AL, Stockmann, C, Rubinstein, MP, Liao, D, Zhang, N, DeNardo, DG et al. (2010). Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70: 7465-7475.
12. Roland, CL, Lynn, KD, Toombs, JE, Dineen, SP, Udugamasooriya, DG and Brekken, RA (2009). Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE 4: e7669.
13. Roland, CL, Dineen, SP, Lynn, KD, Sullivan, LA, Dellinger, MT, Sadegh, L et al. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8: 1761-1771.
14. Sullivan, LA, Carbon, JG, Roland, CL, Toombs, JE, Nyquist-Andersen, M, Kavlie, A et al. (2010). r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS ONE 5: e12031.
15. Brekken, RA, Overholser, JP, Stastny, VA, Waltenberger, J, Minna, JD and Thorpe, PE (2000). Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60: 5117-5124.
16. Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Melcher, A et al. (2011). VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther 19: 150-158.
17. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
18. Aghi, M, Rabkin, SD and Martuza, RL (2007). Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 67: 440-444.
19. Sahin, TT, Kasuya, H, Nomura, N, Shikano, T, Yamamura, K, Gewen, T et al. (2012). Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther 19: 229-237.
20. Fu, X, Tao, L, Rivera, A, Xu, H and Zhang, X (2011). Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity. Cancer Gene Ther 18: 785-794.
21. Libertini, S, Iacuzzo, I, Perruolo, G, Scala, S, Ieranò, C, Franco, R et al. (2008). Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 14: 6505-6514.
22. Zhang, W, Fulci, G, Buhrman, JS, Stemmer-Rachamimov, AO, Chen, JW, Wojtkiewicz, GR et al. (2012). Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 20: 37-45.
23. Mahller, YY, Vaikunth, SS, Ripberger, MC, Baird, WH, Saeki, Y, Cancelas, JA et al. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68: 1170-1179.
24. Wong, RJ, Chan, MK, Yu, Z, Ghossein, RA, Ngai, I, Adusumilli, PS et al. (2004). Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10: 4509-4516.
25. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Canron, X et al. (2006). Dominantnegative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 12: 6791-6799.
26. Liu, TC, Zhang, T, Fukuhara, H, Kuroda, T, Todo, T, Martuza, RL et al. (2006). Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 14: 789-797.
27. Hardcastle, J, Kurozumi, K, Dmitrieva, N, Sayers, MP, Ahmad, S, Waterman, P et al. (2010). Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18: 285-294.
28. Yoo, JY, Haseley, A, Bratasz, A, Chiocca, EA, Zhang, J, Powell, K et al. (2012). Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 20: 287-297.
29. Endo, T, Toda, M, Watanabe, M, Iizuka, Y, Kubota, T, Kitajima, M et al. (2002). In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 9: 142-148.
30. Toda, M, Rabkin, SD, Kojima, H and Martuza, RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393.
31. Todo, T, Martuza, RL, Dallman, MJ and Rabkin, SD (2001). In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 61: 153-161.
32. Todo, T, Rabkin, SD, Sundaresan, P, Wu, A, Meehan, KR, Herscowitz, HB et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755.
33. Eshun, FK, Currier, MA, Gillespie, RA, Fitzpatrick, JL, Baird, WH and Cripe, TP (2010). VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther 17: 922-929.
34. Currier, MA, Adams, LC, Mahller, YY and Cripe, TP (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 12: 407-416.